Provided by Tiger Fintech (Singapore) Pte. Ltd.

Insmed

70.80
-0.4400-0.62%
Pre-market: 70.940.1400+0.20%05:08 EDT
Volume:1.49M
Turnover:106.02M
Market Cap:12.87B
PE:-12.71
High:72.71
Open:72.53
Low:70.63
Close:71.24
Loading ...

New England Journal of Medicine Publishes Positive Results from Insmed's Pivotal Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis

PR Newswire
·
12 hours ago

Insmed says NEJM publishes ‘positive’ results from Phase 3 ASPEN study

TIPRANKS
·
12 hours ago

Insmed Inc : Bofa Global Research Cuts Price Objective to $95 From $96

THOMSON REUTERS
·
Yesterday

Insmed to Host First-Quarter 2025 Financial Results Conference Call on Thursday, May 8, 2025

PR Newswire
·
Yesterday

Insmed Price Target Maintained With a $90.00/Share by HC Wainwright & Co.

Dow Jones
·
22 Apr

Insmed’s Brensocatib: A Promising Solution for Bronchiectasis in AATD Patients

TIPRANKS
·
22 Apr

Should iShares Morningstar Small-Cap ETF (ISCB) Be on Your Investing Radar?

Zacks
·
21 Apr

Insmed’s Chief Commercial Officer Resigns for Personal Reasons

TIPRANKS
·
18 Apr

Analysts Offer Insights on Healthcare Companies: Insmed (INSM), Community Health (CYH) and Argenx Se (ARGX)

TIPRANKS
·
11 Apr

Insmed (INSM) Gets a Buy from Mizuho Securities

TIPRANKS
·
09 Apr

Is Insmed Incorporated (INSM) the Best Long Term Growth Stock to Buy According to Billionaires?

Insider Monkey
·
09 Apr

Insmed participates in a conference call with Cantor Fitzgerald

TIPRANKS
·
08 Apr

RBC Capital Keeps Their Buy Rating on Insmed (INSM)

TIPRANKS
·
05 Apr

Insmed Incorporated (INSM): Insiders Were Dumping in Q1 2025

Insider Monkey
·
02 Apr

Biotech stocks have been hit by 'DOGE' and other fears. Why they're a great value now.

Dow Jones
·
27 Mar

Is Insmed Incorporated (INSM) a Promising Biotech Stock According to Wall Street Analysts

Insider Monkey
·
26 Mar

Wells Fargo Sticks to Their Buy Rating for Insmed (INSM)

TIPRANKS
·
24 Mar

Insmed Is Maintained at Buy by B of A Securities

Dow Jones
·
20 Mar

Insmed Inc : Bofa Global Research Raises Price Objective to $96 From $92

THOMSON REUTERS
·
20 Mar

Insmed (INSM) Gets a Buy from Mizuho Securities

TIPRANKS
·
19 Mar